Valuation : Savara Inc.

Market Cap 1.36B 1.17B 1.1B 1.01B 1.89B 129B 1.9B 13.04B 5.08B 65.64B 5.1B 4.99B 218B P/E 2026 *
-9.28x
P/E 2027 * -15.8x
Enterprise Value 1.36B 1.17B 1.1B 1.01B 1.89B 129B 1.9B 13.04B 5.08B 65.64B 5.1B 4.99B 218B EV / Sales 2026 *
674x
EV / Sales 2027 * 16.6x
Free-Float
97.41%
Yield 2026 *
-
Yield 2027 * -
08-25 Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution in Autoimmune Pulmonary Alveolar Proteinosis At the European Respiratory Society Congress 2026 CI
08-12 Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-23 Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing MT
06-09 Savara Inc. Announces CFO Changes CI
06-09 Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 CI
05-18 Savara Inc Announces New Exercise Capacity Data From The IMPALA-2 Phase 3 Clinical Trial Of Molgramostim Inhalation Solution In Autoimmune Pulmonary Alveolar Proteinosis CI
05-13 Savara Q1 Loss Widens MT
05-13 Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss MT
05-13 Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating MT
04-16 Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP) RE
04-16 Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application MT
04-16 Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis CI
1 day-0.74%
1 week-4.46%
Current month-0.74%
1 month-2.01%
3 months+3.88%
6 months-11.13%
Current year-11.28%
1 week 5.21
Extreme 5.21
5.66
1 month 5.14
Extreme 5.14
5.99
Current year 4.7
Extreme 4.695
6.49
1 year 3.32
Extreme 3.32
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 58 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 72 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

Chief Financial Officer

105,000 0.0512%
18/03/26 Exercice

Chief Financial Officer

850,254 0.4179%
16/02/26 Exercice

Director

3,614 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%-4.46%+63.11%+39.32% 1.36B
-0.25%-4.10%+38.38%+92.61% 68.21B
+0.88%-0.40%+47.52%+88.25% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.44%+0.56%+31.42%-18.48% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.86%-5.09%-0.92%+536.19% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average +0.01%-3.98%+47.19%+187.45% 26.45B
Weighted average by Cap. +0.12%-3.23%+41.70%+157.95%

Financials

2026 *2027 *
Net sales 2.02M 1.74M 1.64M 1.49M 2.8M 191M 2.82M 19.35M 7.53M 97.39M 7.57M 7.41M 323M 81.97M 70.71M 66.51M 60.59M 114M 7.78B 115M 786M 306M 3.96B 308M 301M 13.12B
Net income -147M -127M -119M -109M -204M -13.95B -205M -1.41B -549M -7.1B -552M -540M -23.53B -78.73M -67.91M -63.88M -58.2M -109M -7.47B -110M -755M -294M -3.8B -296M -289M -12.6B
Net Debt - -
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
01/09/26 $5.350 -0.74% 1,042,127
31/08/26 $5.390 +2.47% 1,958,683
28/08/26 $5.260 -4.19% 1,336,330
27/08/26 $5.490 -2.14% 1,595,887
26/08/26 $5.610 +0.18% 1,529,844
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.350USD
Average target price
10.94USD
Spread / Average Target
+104.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SVRA Stock